(HRZN) Horizon Technology Finance - Ratings and Ratios
Secured Debt, Venture Lending, Technology, Life Science, Healthcare
HRZN EPS (Earnings per Share)
HRZN Revenue
Description: HRZN Horizon Technology Finance
Horizon Technology Finance Corporation is a business development company that specializes in lending and investing in development-stage companies, primarily in the technology, life science, healthcare, and cleantech sectors. The companys investment strategy focuses on secured debt and venture lending to venture capital-backed companies in the United States.
Key performance indicators (KPIs) for HRZN include its dividend yield, which is an important metric for income-focused investors. With a history of paying consistent dividends, HRZNs yield can be compared to its peers in the business development company (BDC) space. Additionally, the companys net asset value (NAV) per share, which is a measure of its intrinsic value, is another crucial KPI to monitor. A rising NAV indicates increasing value for shareholders.
HRZNs investment portfolio composition is also a vital aspect to analyze. The companys exposure to various industries, such as technology and life sciences, and its diversification across different stages of company development, can impact its overall performance. Furthermore, the credit quality of its loan portfolio, measured by metrics such as non-accrual rates and debt-to-equity ratios, is essential in assessing the companys risk profile.
To evaluate HRZNs financial health, investors can examine its debt-to-equity ratio, interest coverage ratio, and return on equity (ROE). While the provided ROE of -0.97 indicates a negative return, it is essential to consider this metric in the context of the companys overall performance and industry benchmarks. Other relevant metrics, such as the companys net investment income (NII) per share and its regulatory capital ratios, can provide further insights into HRZNs financial stability.
HRZN Stock Overview
| Market Cap in USD | 297m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 2010-10-29 |
HRZN Stock Ratings
| Growth Rating | -35.4% |
| Fundamental | 39.1% |
| Dividend Rating | 82.5% |
| Return 12m vs S&P 500 | -37.5% |
| Analyst Rating | 3.0 of 5 |
HRZN Dividends
| Dividend Yield 12m | 21.79% |
| Yield on Cost 5y | 23.31% |
| Annual Growth 5y | 1.10% |
| Payout Consistency | 88.3% |
| Payout Ratio | 38.6% |
HRZN Growth Ratios
| Growth Correlation 3m | -16.8% |
| Growth Correlation 12m | -78.7% |
| Growth Correlation 5y | -15.6% |
| CAGR 5y | -0.52% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | 0.69 |
| Alpha | -38.55 |
| Beta | 0.576 |
| Volatility | 28.00% |
| Current Volume | 532.7k |
| Average Volume 20d | 629.6k |
| Stop Loss | 6.6 (-4.3%) |
| Signal | -1.34 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-14.8m TTM) > 0 and > 6% of Revenue (6% = 3.76m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -0.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 40.05% (prev 83.35%; Δ -43.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 4.97m > Net Income -14.8m (YES >=105%, WARN >=100%) |
| Net Debt (400.5m) to EBITDA (15.2m) ratio: 26.31 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.81 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (41.2m) change vs 12m ago 16.33% (target <= -2.0% for YES) |
| Gross Margin 75.99% (prev 85.21%; Δ -9.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.29% (prev 12.52%; Δ -4.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.07 (EBITDA TTM 15.2m / Interest Expense TTM 33.0m) >= 6 (WARN >= 3) |
Altman Z'' -1.18
| (A) 0.03 = (Total Current Assets 39.0m - Total Current Liabilities 13.9m) / Total Assets 726.8m |
| (B) -0.35 = Retained Earnings (Balance) -251.7m / Total Assets 726.8m |
| (C) 0.05 = EBIT TTM 35.4m / Avg Total Assets 757.1m |
| (D) -0.57 = Book Value of Equity -251.6m / Total Liabilities 443.0m |
| Total Rating: -1.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.13
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield 0.61% = 0.30 |
| 3. FCF Margin 7.92% = 1.98 |
| 4. Debt/Equity 1.93 = 0.87 |
| 5. Debt/Ebitda 36.00 = -2.50 |
| 6. ROIC - WACC 0.02% = 0.03 |
| 7. RoE -4.68% = -0.78 |
| 8. Rev. Trend -16.67% = -0.83 |
| 9. Rev. CAGR -55.61% = -2.50 |
| 10. EPS Trend -37.50% = -0.94 |
| 11. EPS CAGR -68.00% = -2.50 |
What is the price of HRZN shares?
Over the past week, the price has changed by -1.00%, over one month by -13.89%, over three months by -4.98% and over the past year by -27.13%.
Is Horizon Technology Finance a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRZN is around 7.75 USD . This means that HRZN is currently undervalued and has a potential upside of +12.32% (Margin of Safety).
Is HRZN a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HRZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.8 | -2.2% |
| Analysts Target Price | 6.8 | -2.2% |
| ValueRay Target Price | 8.3 | 19.9% |
Last update: 2025-08-25 04:38
HRZN Fundamental Data Overview
CCE Cash And Equivalents = 24.7m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 10.0402
P/S = 3.057
P/B = 1.0464
P/EG = 2.07
Beta = 0.978
Revenue TTM = 62.7m USD
EBIT TTM = 35.4m USD
EBITDA TTM = 15.2m USD
Long Term Debt = 429.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 118.9m USD (from shortTermDebt, last quarter)
Debt = 548.0m USD (Calculated: Short Term 118.9m + Long Term 429.1m)
Net Debt = 400.5m USD (from netDebt column, last quarter)
Enterprise Value = 820.3m USD (297.0m + Debt 548.0m - CCE 24.7m)
Interest Coverage Ratio = 1.07 (Ebit TTM 35.4m / Interest Expense TTM 33.0m)
FCF Yield = 0.61% (FCF TTM 4.97m / Enterprise Value 820.3m)
FCF Margin = 7.92% (FCF TTM 4.97m / Revenue TTM 62.7m)
Net Margin = -23.65% (Net Income TTM -14.8m / Revenue TTM 62.7m)
Gross Margin = 75.99% ((Revenue TTM 62.7m - Cost of Revenue TTM 15.1m) / Revenue TTM)
Tobins Q-Ratio = -3.26 (set to none) (Enterprise Value 820.3m / Book Value Of Equity -251.6m)
Interest Expense / Debt = 1.50% (Interest Expense 8.20m / Debt 548.0m)
Taxrate = 21.0% (US default)
NOPAT = 27.9m (EBIT 35.4m * (1 - 21.00%))
Current Ratio = 2.81 (Total Current Assets 39.0m / Total Current Liabilities 13.9m)
Debt / Equity = 1.93 (Debt 548.0m / last Quarter total Stockholder Equity 283.8m)
Debt / EBITDA = 36.00 (Net Debt 400.5m / EBITDA 15.2m)
Debt / FCF = 110.3 (Debt 548.0m / FCF TTM 4.97m)
Total Stockholder Equity = 317.0m (last 4 quarters mean)
RoA = -2.04% (Net Income -14.8m, Total Assets 726.8m )
RoE = -4.68% (Net Income TTM -14.8m / Total Stockholder Equity 317.0m)
RoCE = 4.74% (Ebit 35.4m / (Equity 317.0m + L.T.Debt 429.1m))
RoIC = 3.65% (NOPAT 27.9m / Invested Capital 765.6m)
WACC = 3.63% (E(297.0m)/V(845.0m) * Re(8.14%)) + (D(548.0m)/V(845.0m) * Rd(1.50%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 18.90%
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.56% ; FCFE base≈5.86m ; Y1≈4.78m ; Y5≈3.37m
Fair Price DCF = 1.44 (DCF Value 61.3m / Shares Outstanding 42.5m; 5y FCF grow -22.17% → 3.0% )
Revenue Correlation: -16.67 | Revenue CAGR: -55.61%
Rev Growth-of-Growth: -151.7
EPS Correlation: -37.50 | EPS CAGR: -68.00%
EPS Growth-of-Growth: 107.9
Additional Sources for HRZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle